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Abstract
Vitamin D exerts an immuno-modulatory activity on several immune system cells through the vitamin D receptor
(VDR). Herein, we verified that age and a therapeutic regimen containing protease inhibitors are associated with fail-
ures in antiretroviral therapies (ARVs). In addition, we assessed whether a VDR SNP (rs11568820: C allele and CC
genotype) and GC (rs2228570-rs11568820) allelic combinations are associated with immunological failure (p <
0.05). Our findings suggest a possible role of VDR SNPs on immunological failure in HIV-1+ individuals undergoing
regular ARVs.
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Antiretroviral therapies (ARVs) have changed the
landscape of Human Immunodeficiency Virus (HIV) treat-
ment in the last years. ARVs act by boosting immune func-
tions and reducing morbidity and mortality by suppressing
viral replication (Palella et al., 2006). There is no “one fits
all” therapy, since some individuals receiving ARVs are
not able to suppress the viral load to undetectable levels as
expected (virological failure) (Coelho et al., 2013). On the
other hand, some individuals with undetectable viral load,
cannot recover the quasi-normal CD4+ T-cell count (im-
munological failure) (Kelley et al., 2009). These phenom-
ena might be due to the hosts’ genetics, immunological
factors, and viral profiles (Geretti et al., 2009; Robbins et
al., 2009).
1,25-dihydroxy vitamin D (1,25[OH]2D) exerts po-
tent immunologic roles in both innate and adaptive re-
sponses. Its binding with vitamin D receptor (VDR) pro-
motes a series of intracellular events culminating in the
modulation of expression levels of various target genes.
These effects may promote the control of intracellular pa-
thogens, mainly by producing antimicrobial peptides, and
stimulating phagocytic activity in macrophages (Prietl et
al., 2013).
In HIV-1 infection, variable levels of 1,25[OH]2D
may decrease the immune system activation during the
acute phase, or induce a less effective T-helper lymphocyte
response throughout the chronic phase (Appay and Sauce,
2008; Giusti and Penco, 2011). Indeed, individuals with ad-
equate levels of this vitamin, have been seen to better coun-
teract HIV replication (Lake and Adams, 2011).
In addition, ARVs may alter the circulating levels of
25-hydroxy vitamin D (25[OH]D) (1,25[OH]2D metabolic
precursor), as these compounds share common cytochrome
P450 enzymes involved in their synthesis (1,25[OH]2D)
and excretory (ARVs) metabolic pathways (Mueller et al.,
2010; Welz et al., 2010). Interestingly, 1,25[OH]2D insuffi-
ciency/deficiency has been associated with the usage of
ARVs (Cozzolino et al., 2003; Brown and McComsey,
2010).
Single nucleotide polymorphisms (SNPs) in the VDR
gene (12q13.11) have been associated to susceptibility and
progression of HIV/AIDS, since they may alter gene func-
tion and compromise the role of 1,25[OH]2D (de la Torre et
al., 2008; Alagarasu et al., 2009; Aguilar-Jiménez et al.,
2013; Laplana et al., 2014). However, there are no reports
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associating these genetic variants with successful treatment
and immune recovery.
In this work, we investigated the distribution of VDR
SNPs in HIV-1 infected individuals (HIV-1+) to unravel
their relation with treatment response and immune recov-
ery.
We analyzed 195 HIV-1+ individuals from Recife
and minor towns of the state of Pernambuco (Northeastern
Brazil), recruited from 2011 to 2014 at the Institute of Inte-
gral Medicine Professor Fernando Figueira (Human Re-
search Ethics Committee register nr. 2629-13). Individuals
lacking pre-existing viral hepatitis co-infection, and who
have adhered for at least one year to ARVs have been
selected for this study (Coelho et al., 2013). The studied
population was stratified into 132 individuals with unde-
tectable viral load (< 50 copies/mL) (virological suc-
cess/suppression) and 63 individuals having detectable vi-
ral load (> 50 copies/mL) (virological failure). In addition,
based on the comparison between CD4+ T-cell count be-
fore treatment (baseline) and after one year of treatment (Li
et al., 2011), individuals possessing virological suppres-
sion were divided as immunological success (65) (recovery
of CD4+ > 200 cells/mm3) and immunological failure (67)
(non-recovery CD4+ < 200 cells/mm3).
Individuals manifesting virological failure were mos-
tly female (66.7%), with a median age of 35 years
(p=0.009, Mann-Whitney test), and receiving therapeutic
regimens containing protease inhibitors (2 non-nucleoside
reverse transcriptase inhibitor + protease inhibitor
[NNRTI+PI]; 55.6%, p=0.037, Chi-square test). Further-
more, the NNRTI-containing regimen resulted more fre-
quently in individuals with immunological failure (68.7%)
in comparison to the immunological successful ones
(53.1%, p=0.047, Chi-square test) (Table 1).
Studies in Latin American populations (Bello et al.,
2011; Alave et al., 2013; Cesar et al., 2015) also identified
as risk factors for virological failure parameters such as
younger age (20 years), infection pathway (Cesar et al.,
2015), antiretroviral use history before starting a new ther-
apy regimen, therapy change due to toxicity, opportunistic
infections, baseline CD4+ T-cells count below 100
cells/L, adherence, advanced clinical stage (Alave et al.,
2013), geographical origin, and Mycobacterium tuberculo-
sis co-infection (Bello et al., 2011).
Besides the clinical-epidemiological characteristics,
a panel of four tag-SNPs in the intronic region within the
VDR gene (rs3890733, rs4760648, rs1540339, rs2248098)
and two functional ones, namely rs2228570 (Fok1 – mis-
sense variation – stat lost) and rs11568820 (Cdx2 – regula-
tory variation) were studied. SNP selection was based on
public data bank as well as literature data (de la Torre et al.,
2008; Alagarasu et al., 2009; Laplana et al., 2014; Xu et al.,
2015). All variants were genotyped using allele-specific
fluorogenic probes by real-time PCR and presented minor
allele frequency (MAF)  10% in Caucasian (CEU) and
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Table 1 - Clinical and Epidemiological characteristics of the study population.
Virologic Response Immunological Response
Characteristics Success (n=132) Failure (n=63) Univariate analysis Success (n=65) Failure (n=67) Univariate analysis
Sex, n (%)
Female 72 (54.5) 42 (66.7) X2=2.1052, df=1,
p-value= 0.147
40 (61.5) 32 (47.8) X2=1.7736, df=1,
p-value=0.183
Male 60 (45.5) 21 (33.3) 25 (38.5) 35 (52.2)
Age
Median years (IQR) 38.0
(34.0-46.0)
35.0
(31.5-41.0)
W=3201,
p-value=0.009*
37.0
(34.0-46.0)
38.0
(34.0-45.0)
W=2015,
p-value=0.528
Weight
Median kilograms (IQR) 62.0
(54.2-74.0)
62.7
(55.0-73.2)
W=4043.5,
p-value=0.500
63.0
(53.0-74.0)
62.0
(56.0-74.0)
W=1858,
p-value=0.630
Baseline viral load
Median log10 copies/mL(IQR) 4.40
(3.02-5.10)
3.78
(2.85-4.91)
W=3417.5,
p-value=0.526
4.52
(3.68-5.06)
4.31
(2.36-5.11)
W=1741,
p-value=0.451
CD4+ T cells count baseline
Median cells/mm3 (IQR) 282.0
(165.0-365.0)
291.0
(179.0-410.0)
W=3883,
p-value=0.769
282
(200.5-433.0)
282.5
(126.0-343.7)
W=1567,
p-value=0.178
HAART regimens, n (%)
NNRTI use 80 (61.1) 28 (44.4) X2= 4.3617, df=1,
p-value=0.037*
32 (53.1) 43 (68.7) X2= 3.9558, df=1,
p-value=0.047*
PI use 50 (38.9) 35 (55.6) 29 (46.9) 17 (31.3)
n= Sample size; IQR = Interquartile range; X2= Result from chi-squared test; df = Degrees of freedom; W =Result from Mann-Whitney test; * = Signifi-
cant p-value.
Yoruba (YRI) populations, considering them as proxies to
Brazil’s ancestral populations (Coelho et al., 2015).
Allelic and genotypic frequencies of VDR SNPs in
treatment and immunological response groups are reported
in Table 1. All the considered SNPs studied were in accor-
dance with Hardy-Weinberg equilibrium in all groups, ex-
cept for SNP rs3890733. No significant differences were
observed for the tested SNPs relative to treatment response,
but the SNP rs11568820 (C > T) was found to be associated
with immune recovery.
The C allele (rs11568820) was significantly more fre-
quent in individuals presenting immunological failure
(62.1%), rather than in those showing immunological suc-
cess (48.4%; OR=1.74; 95%CI=1.01-3.03; p=0.037, Fi-
sher’s exact test). Similarly, the C/C genotype was signifi-
cantly more frequent in immunological failure (34.5%) in
comparison to individuals with immunological success
(19.7%; OR=3.78; 95%CI=1.03-15.57; p=0.045, Fisher’s
exact test) (Table 2).
No haplotype block was observed for VDR functional
SNPs in all studied groups (D’ > 0.20). Allelic combination
analyses revealed that only the GC allele combination
(rs2228570-rs11568820) was associated with immunologi-
cal failure (OR=2.19; 95%CI=1.09-4.45; p=0.023, Fisher’s
exact test) (Table S1).
Two multivariate analyses were performed contain-
ing variables with p  0.2 obtained during univariate analy-
ses. Age, gender, antiretroviral drugs classes, and
rs2248098 genotypes were included as clinic-epidemio-
logical and genetic variables to assess whether they influ-
enced the overall virological response, but no significant
associations were found. The second analysis included the
pre-treatment (baseline) CD4+ T-cells count, gender, and
antiretroviral drugs classes. In the second multivariate anal-
ysis we intended to assess whether rs2248098 and
rs11568820 genotypes had any influence on immunologi-
cal response. Again, the rs11568820 C/C genotype was as-
sociated with immunological failure (OR=6.00;
95%CI=1.52-23.72; p-value=0.01) (Table S2).
None of the studied SNPs were involved in viral load
control before treatment and CD4+ T-cell count baseline,
even when classified according to virological treatment re-
sponse or immunological recovery (p-values > 0.05; Kru-
skal-Wallis test, data not shown).
The C allele and C/C genotype of SNP rs11568820
and the GC allelic combination (rs2228570-rs11568820)
were associated with immunological failure in individuals
that achieved the viral load suppression following ARVs.
The understanding of this immunological impairment in vi-
ral-suppressed HIV-1 individuals remains elusive mainly
due to its multifactorial character. In our work, we ad-
dressed a SNP as a candidate for contributing in the im-
mune recovery modulation. The rs11568820 SNP (known
as Cdx-2), located within the VDR promoter region, acts at
the transcriptional level. Therefore, the presence of the C
allele (rs11568820) may result in a decreased transcriptio-
nal activity and, consequently, in lower VDR expression
(Arai et al., 2001).
Finally, the levels of 25(OH)D in plasma were ob-
tained from medical records of 31 individuals deriving
from our sample groups (19 immunological success and 12
immunological failure). A Cochran-Mantel-Haenszel test
was applied to assess whether the interaction between
25(OH)D plasma levels and VDR genotypes had an impact
on immunological failure risk, thus following the hypothe-
sis that some VDR genotypes would not respond to
25(OH)D levels, even if they are adequate. However, no
significant differences were found (success group me-
dian=35.2, IQR=28.1-41.1; failure group median=32.9,
IQR=31.4-41.0; W=109; p-value=0.86, Table S3). Next,
we stratified the individuals according to VDR genotypes
and insufficient/sufficient status and evaluated, through a
Cochran-Mantel-Haenszel test, whether the genotypes ver-
sus 25(OH)D influenced the risk of immunological failure.
Also in this case, no associations were observed. Even defi-
cient 25(OH)D levels have been found not to be associated
with immunological failure, irrespective of VDR genotype
(data not shown).
We did not identify relationships between plasma lev-
els and immunological failure, in spite of a VDR-associated
genotype (rs11568820). This fact may be related to the
small number of individuals used in the dosage and/or the
absence of a proper classification of studied individuals re-
ferred to the infection stage, which in our population is al-
most impossible to perform, since the vast majority of HIV
infected cases have a late diagnosis, thus arriving at health
services presumably in a chronic stage, and finally the lack
of control regarding seasonal variation in vitamin D. In our
cohort it is assumed that such inter-individual variation is
small, as there is a regular incidence of solar rays in the geo-
graphic region.
Nonetheless, we believe that individuals with immu-
nological failure and VDR genotype (CC – rs11568820), re-
lated to low expression of VDR, can impair 1,25[OH]2D ac-
tion, since its activity occurs through VDR binding
(Selvaraj et al., 2012). A reduced 1,25[OH]2D activity
compromises cell-mediated immune response, phagocytic
activity in macrophages (Deluca and Cantorna 2001; Prietl
et al., 2013), suppresses T-cell activation, downregulates
pro-inflammatory cytokine production, and decreases
anti-microbial defence by peptides, which in turn impair vi-
ral replication (Beard et al., 2011).
Furthermore, Chandel et al. (2013) demonstrated that
down-regulation of VDR expression in T-cells deriving
from HIV-1+ individuals is due to hypermethylation in the
promoter region. These epigenetic alterations increase the
activation of the renin angiotensin system (RAS) and reac-
tive oxygen species (ROS) production, inducing double-
strand breaks (DSBs) and attenuated DNA repair response,
therefore favouring T-cell apoptosis.
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ARVs themselves might further compromise the ac-
tion of 1,25[OH]2D, since some antiretroviral drugs (efa-
virenz, tenofovir and ritonavir) have been associated with
changes in plasma levels of 1,25[OH]2D (Welz et al., 2010;
Dao et al., 2011). In our cohort, amongst individuals with
available dosage, we observed that 50% of the cases
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Table 2 - Allelic and genotypic frequencies of VDR SNPs in HIV-1+ patients in HAART treatment as to the virological and immunological response.
SNPs Virological Fisher’s Exact Test Immunological Fisher’s Exact Test
Success n (%) Failure n (%) OR (95% CI), p-value Success n (%) Failure n (%) OR (95% CI), p-value
rs2248098
G 125 (54.3) 52 (46.4) Reference 62 (55.4) 63 (53.4) Reference
A 105 (45.7) 60 (53.6) 1.37 (0.85-2.22), 0.205 50 (44.6) 55 (46.6) 1.08 (0.62-1.88), 0.792
GG 34 (29.6) 12 (21.4) Reference 20 (35.7) 14 (23.7) Reference
GA 57 (49.6) 28 (50.0) 1.39 (0.59-3.41), 0.551 22 (39.3) 35 (59.3) 2.25 (0.88-5.93), 0.082
AA 24 (20.9) 16 (28.6) 1.87 (0.69-5.22), 0.249 14 (25.0) 10 (16.9) 1.02 (0.31-3.34), 1.000
rs1540339
C 167 (69.6) 77 (67.5) Reference 85 (70.8) 82 (68.3) Reference
T 73 (30.4) 37 (32.5) 1.10 (0.66-1.82), 0.713 35 (29.2) 38 (31.7) 1.12 (0.62-2.03), 0.779
CC 59 (49.2) 28 (49.1) Reference 31 (51.7) 28 (46.7) Reference
CT 49 (40.8) 21 (36.8) 0.90 (0.43-1.88), 0.863 23 (38.3) 26 (43.3) 1.25 (0.55-2.86), 0.699
TT 12 (10.0) 8 (14.0) 1.40 (0.44-4.23), 0.601 6 (10.0) 6 (10.0) 1.10 (0.26-4.67), 1.000
rs2228570
G 180 (69.8) 87 (71.3) Reference 83 (65.9) 97 (73.5) Reference
A 78 (30.2) 35 (28.7) 0.93 (0.56-1.52), 0.811 43 (34.1) 35 (26.5) 0.70 (0.39-1.23), 0.222
GG 63 (48.8) 29 (47.5) Reference 27 (42.9) 36 (37.9) Reference
GA 54 (41.9) 29 (47.5) 1.16 (0.59-2.30), 0.748 29 (46.0) 25 (37.9) 0.65 (0.29-1.43), 0.269
AA 12 (9.3) 3 (4.9) 0.54 (0.09-2.24), 0.545 7 (11.1) 5 (7.6) 0.54 (0.12-2.22), 0.359
rs4760648
T 98 (53.3) 40 (58.8) Reference 52 (55.3) 46 (51.1) Reference
C 86 (46.7) 28 (41.2) 0.80 (0.43-1.45), 0.477 42 (44.7) 44 (48.9) 1.18 (0.66-2.20), 0.658
TT 26 (28.3) 13 (38.2) Reference 14 (29.8) 12 (26.7) Reference
TC 46 (50.0) 14 (41.2) 0.61 (0.23-1.65), 0.356 24 (51.1) 22 (48.9) 1.07 (0.37-3.14), 1.000
CC 20 (21.7) 7 (20.6) 0.70 (0.20-2.33), 0.593 9 (19.1) 11 (24.4) 1.41 (0.38-5.39), 0.767
rs3890733 §
C 149 (64.8) 67 (67.0) Reference 78 (67.2) 71 (62.3) Reference
T 81 (35.2) 33 (33.0) 0.91 (0.53-1.53), 0.801 38 (32.8) 43 (37.7) 1.24 (0.70-2.22), 0.490
CC 58 (50.4) 26 (52.0) Reference 32 (55.2) 26 (45.6) Reference
CT 33 (28.7) 15 (30.0) 1.01 (0.43-2.32), 1.000 14 (24.1) 19 (33.3) 1.66 (0.65-4.34), 0.280
TT 24 (20.9) 9 (18.0) 0.84 (0.30-2.19), 0.824 12 (20.7) 12 (21.1) 1.23 (0.42-3.56), 0.808
rs11568820
T 109 (45.4) 50 (46.3) Reference 63 (51.6) 44 (37.9) Reference
C 131 (54.6) 58 (53.7) 0.96 (0.60-1.56), 0.908 59 (48.4) 72 (62.1) 1.74 (1.01-3.03), 0.037*
TT 21 (17.5) 12 (22.2) Reference 14 (23.0) 6 (10.3) Reference
CT 67 (55.8) 26 (48.1) 0.68 (0.27-1.75), 0.384 35 (57.4) 32 (55.2) 2.11 (0.66-7.56), 0.203
CC 32 (26.7) 16 (29.6) 0.88 (0.31-2.47), 0.815 12 (19.7) 20 (34.5) 3.78 (1.03-15.57), 0.045*
n = Sample size; OR = Odds ratios; 95% CI = 95% Confidence interval; * = significant p-value; § = not Hardy-Weinberg Equilibrium.
showing immunological failure used a NNTRI-containing
regimen and 50% received a PI-containing treatment.
Among the individuals with immunological success, ap-
proximately 42% used a NNTRI-containing therapy,
against 58% who used PI.
We cannot fail to recognize our limitations. Firstly,
the small sample number is directly linked to the individu-
als treatment adherence. Despite a large number of patients
undergoing treatment, the majority had low ARVs adher-
ence. Secondly, for some SNPs the number of genotyped
individuals resulted different in relations to others due to
the quality of the biological samples, implying technical
difficulties in the genotyping process. A further limitation
was due to the lack of VDR expression analysis caused by
the impossibility to extract RNA from certain biological
samples.
In conclusion, our results lead us to hypothesize (Fig-
ure 1) that genetic variations in VDR (rs11568820 – C al-
lele and C/C genotype; CG allelic combination) might
decrease VDR expression, influencing the binding of
1,25[OH]2D to VDR (possibly disrupting the 1,25[OH]2D
action) and inducing apoptosis, consequently affecting
CD4+ T-cells recovery. Our work reports for the first time
the existence of a relationship between SNPs in the VDR
gene and the immunological recovery in HIV-1 + individu-
als undergoing ARVs.
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